Industry News
Pharmaceutical Industry News
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
On the heels of favorable court…
On the heels of favorable court rulings, Johnson & Johnson has forged an agreement with law firms for plaintiffs that claim Johnson’s Baby Powder caused their ovarian cancer. J&J has proposed a $5.5 billion settlement
About half a year into his tenure…
About half a year into his tenure as GSK’s CEO, Luke Miels is launching a three-year restructuring designed to generate $2.5 billion in annual cost savings by 2029. The cost reductions will mainly be pulled
Baxter issued a voluntary recall…
Baxter issued a voluntary recall of one lot of cefazolin in dextrose injection after a report that cardboard was found in an IV infusion bag.
Havas Lynx has shaken up the…
Havas Lynx has shaken up the leadership of its New York team, expanding Claire Knapp’s role to cover the office and hiring Bruno Rebelo to head up its creative division.
Gilead’s “Up to Date” campaign…
Gilead's "Up to Date" campaign features comedians Nicole Byer and Devon Walker and looks to destigmatize HIV conversations in the Black community, which has historically been dispropriationally impacted by HIV.
Some five months after announcing…
Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta Therapeutics has found
Approval of the first-in-class…
Approval of the first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) gives the Japanese drugmaker its “next major CNS launch” and positions the therapy to become a potential blockbuster in a large, under-penetrated market, Jefferies analysts
Roche’s cancer treatment Avastin…
Roche’s cancer treatment Avastin has long been employed as an off-label option for wet age-related macular degeneration patients. Now the FDA has endorsed a new formulation of the VEGF inhibitor for regulated use in the
Even as trial setbacks and…
Even as trial setbacks and pipeline adjustments rear their heads, AstraZeneca feels confident that its core business is on track to support the $80 billion revenue goal it’s set for 2030. And on the more
In a sudden leadership shift,…
In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
The Peptide Wild West
Welcome to the new Wild West of peptides.
F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.
As outside experts gathered for a…
As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the U.S.’ bulk compounding list, the first to go up against a vote did not fare as well as those
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of
The company is targeting Lilly ad…
The company is targeting Lilly ad campaigns that cite what Novo calls “outdated” clinical trials comparing Lilly’s drugs with Ozempic and Wegovy.
With all eyes on Tavneos’…
With all eyes on Tavneos’ seemingly precarious approval status in the U.S., Amgen is advancing plans to defend the ANCA-associated vasculitis (AAV) drug it inherited in its $3.7 billion buyout of ChemoCentryx.
Three years after gaining three…
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop the trio. The company has reported the failure of liver disease drug Bylvay in a
A survey of 36 U.S….
A survey of 36 U.S. gastroenterologists found that significant treatment gaps remain in the growing IBD drug market despite an expanding range of therapies.